Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

This study is testing whether giving immunotherapy (toripalimab) combined with gemcitabine and cisplatin chemotherapy before surgery can shrink liver bile duct cancer (intrahepatic cholangiocarcinoma) enough to make it easier to remove and improve long-term outcomes for patients with high-risk tumors. **You may be eligible if...** - You are 18 years or older - You have confirmed intrahepatic cholangiocarcinoma (a type of bile duct cancer inside the liver) that can be surgically removed - Your tumor meets at least one of the high-risk criteria: larger than 5 cm, has vascular invasion, penetrates through the liver lining, invades nearby organs, or has suspicious lymph nodes nearby - You have not had any prior systemic treatment - Your overall physical condition is good (ECOG 0-1) - Your major organ functions are normal **You may NOT be eligible if...** - You have received prior chemotherapy, immunotherapy, or radiation for this cancer - You have serious heart, lung, liver, kidney, or bone marrow problems - You are pregnant or unwilling to use contraception - You have active autoimmune disease or immunodeficiency Talk to your doctor to see if this trial is right for you.